Pancreatic cancer cells intimately interact with a complex microenvironment that influences pancreatic cancer progression. The pancreas is innervated by fibers of the sympathetic nervous system (SNS) and pancreatic cancer cells have receptors for SNS neurotransmitters which suggests that pancreatic cancer may be sensitive to neural signaling. In vitro and non-orthotopic in vivo studies showed that neural signaling modulates tumour cell behavior. However the effect of SNS signaling on tumor progression within the pancreatic microenvironment has not previously been investigated. To address this, we used in vivo optical imaging to non-invasively track growth and dissemination of primary pancreatic cancer using an orthotopic mouse model that replicates the complex interaction between pancreatic tumor cells and their microenvironment. Stress-induced neural activation increased primary tumor growth and tumor cell dissemination to normal adjacent pancreas. These effects were associated with increased expression of invasion genes by tumor cells and pancreatic stromal cells. Pharmacological activation of b-adrenergic signaling induced similar effects to chronic stress, and pharmacological b-blockade reversed the effects of chronic stress on pancreatic cancer progression. These findings indicate that neural b-adrenergic signaling regulates pancreatic cancer progression and suggest b-blockade as a novel strategy to complement existing therapies for pancreatic cancer.
Chronic stress Beta-adrenergic Pancreatic cancer Invasion Beta-blocker Tumor microenvironment a b s t r a c t Pancreatic cancer cells intimately interact with a complex microenvironment that influences pancreatic cancer progression. The pancreas is innervated by fibers of the sympathetic nervous system (SNS) and pancreatic cancer cells have receptors for SNS neurotransmitters which suggests that pancreatic cancer may be sensitive to neural signaling. In vitro and non-orthotopic in vivo studies showed that neural signaling modulates tumour cell behavior. However the effect of SNS signaling on tumor progression within the pancreatic microenvironment has not previously been investigated. To address this, we used in vivo optical imaging to non-invasively track growth and dissemination of primary pancreatic cancer using an orthotopic mouse model that replicates the complex interaction between pancreatic tumor cells and their microenvironment. Stress-induced neural activation increased primary tumor growth and tumor cell dissemination to normal adjacent pancreas. These effects were associated with increased expression of invasion genes by tumor cells and pancreatic stromal cells. Pharmacological activation of b-adrenergic signaling induced similar effects to chronic stress, and pharmacological b-blockade reversed the effects of chronic stress on pancreatic cancer progression. These findings indicate that neural b-adrenergic signaling regulates pancreatic cancer progression and suggest b-blockade as a novel strategy to complement existing therapies for pancreatic cancer.
Ó 2014 Elsevier Inc. All rights reserved.
Introduction
Pancreatic cancer is the fourth leading cause of cancer-related death, with approximately 40,000 new cases in the US each year (Siegel et al., 2012) . The overall survival rate is less than 5% and effective strategies to improve clinical outcomes are critically needed. Survival from pancreatic cancer depends on successful resection of the primary tumor with 5-year survival rates of 20-30% reported in specialized centers (Gaedcke, 2010) . However, even when surgery results in tumor-free resection margins recurrence rates are high and most patients eventually die of local tumor recurrence and metastatic disease (Kleeff, 2007; Hishinuma, 2006; Han, 2006) . Additionally, many patients are diagnosed with advanced stage pancreatic cancer, which limits surgical treatment (Kazanjian, 2008; Bilimoria, 2007) . Gemcitabine is the standard-ofcare chemotherapy regimen for locally advanced and metastatic pancreatic cancer, but the overall prolongation of survival is disappointingly small (5-7 months) (Storniolo, 1999; Herrmann, 2007; Rougier, 2013) . Recent trials of combination chemotherapies and targeted therapeutic strategies including FOLFIRINOX, nab-Paclitaxel and the EGFR inhibitor, erlotinib, have shown additional survival benefit of only days to weeks, with increased toxicity that limits their use to otherwise fit patients (Conroy, 2011 
